NOVELTY - Forming (S)-10-acetoxy-10,11-dihydro-5H-dibenz(b,f)azepine-5-carboxamide involves (a1) reducing 10-oxo-10,11-dihydro-5H-dibenz(b,f)azepine-5-carboxamide with reducing agent in solvent; (b1) condensing 10-hydroxy-10,11-dihydro-5H-dibenz(b,f)azepine-5-carboxamide with amino acid, optionally D-proline derivative in presence of condensing agent; (c1) hydrolyzing dibenz(b,f)azepine ester derivative with acid/base in solvent; (d1) acetylating (S)-10-hydroxy-10,11-dihydro-5H-dibenz(b,f)azepine-5-carboxamide with acetylating agent in presence of base in solvent.    USE - For preparing (S)-10-acetoxy-10,11-dihydro-5H-dibenz(b,f)azepine-5-carboxamide compound (claimed) which is an antiepileptic drug for treating other forms of epilepsy, monotherapy of epilepsy, bipolar disorder and trigeminal neuralgia.    ADVANTAGE - The process has high yields and high purity; uses simple chiral reducing agent in place of Rh(COD)(RcSp-DuanPhos)BF4, (RuCl2(p-cymene))2 plus (S,S)-TsDAEN, which are commercially not available and difficult to prepare; avoids the use of chemicals which are explosive in nature and preventing the possibility of accidents; uses simple, milder and non-toxic reagents which are easier to handle and suitable for large scale process; and is eco-friendly process.    DETAILED DESCRIPTION - Preparing (S)-10-acetoxy-10,11-dihydro-5H-dibenz(b,f)azepine-5-carboxamide compound (I) involves (a1) reducing 10-oxo-10,11-dihydro-5H-dibenz(b,f)azepine-5-carboxamide (II) with a reducing agent in suitable solvent to provide 10-hydroxy-10,11-dihydro-5H-dibenz(b,f)azepine-5-carboxamide compound (IV); (b1) condensing the compound (IV) with suitable amino acid, optionally N-substituted such as D-proline derivative (VI) in presence of a condensing agent in suitable solvent to provide dibenz(b,f)azepine ester derivative of formula (VII), (c1) hydrolyzing the compound (VII) with an acid or base in suitable solvent to provide (S)-10-hydroxy-10,11-dihydro-5H-dibenz(b,f)azepine-5-carboxamide compound (III), (d1) acetylating the compound (III) with an acetylating agent in presence of a base in suitable solvent to provide compound (I), (e1) optionally purifying/isolating the compound obtained in step (d1) from suitable solvent provides pure compound (I). INDEPENDENT CLAIMS are included for the following:    (1) new intermediates (VII) or of formula (IX) or its stereoisomer;    (2) crystalline form-M of (R)-((S)-5-carbamoyl-10,11-dihydro-5H-dibenzo (b,f)azepin-10-yl)1-benzylpyrrolidine-2-carboxylate compound (VIIa) having powder X-ray difiractogram in figure-1 of the specification, having Infrared spectrum in figure-2 of the specification, and having DSC thermogram in figure-3 of the specification;    (3) preparing (P2) (S)-10-hydroxy-10,11-dihydro-5H-dibenz(b,f)azepine-5-carboxamide compound (III), involving either reducing the compound (II) with suitable chiral reducing agent in suitable solvent to provide compound (III), in which the suitable chiral reducing agent is selected from beta -chloro diisopinocampheyl borane (DIP Chloride), or reducing agent like borane-tetrahydrofuran (THF) or borane-DMS in combination with chiral catalyst like R-Methyl CBS or R-Butyl CBS or R-Phenyl CBS; or reducing the compound (II) with Borane-DMS in presence of R-methyl CBS in tetrahydrofuran to provide the compound (III); or hydrolyzing dibenz(b,f)azepine ester derivative (VII) with suitable acid or base in suitable solvent to provide the compound (III); or hydrolyzing the ((R)-((S)-5-carbamoyl-10,11-dihydro-5H-dibenz(b,f)azepin-10-yl)1-benzyl pyrrolidine-2-carboxylate compound (VIIa) with suitable acid or base in a solvent to provide the compound (III);    (4) preparing (P3) dibenz(b,f)azepine ester derivative (VII) involving condensing 10-hydroxy-10,11-dihydro-5H-dibenz(b,f)azepin-5-carboxamide (IV) with suitable amino acid, optionally N-substituted such as D-proline derivative compound (VI) in presence of suitable condensing agent in a solvent provides compound (VII);    (5) usage of diisopropyl ethyl amine as a base in acetylating (S)-10-hydroxy-10,11-dihydro-5H-dibenz(b,f)azepine-5-carboxamide compound (III), to provide the compound (I); and    (6) preparing dibenz(b,f)azepine ester derivative (IX) involving either condensing the compound (IV) with 2-amino-2-phenylacetic acid, in presence of suitable condensing agent in suitable solvent to provide the compound (IX); or condensing the compound (IV) with 2-amino-2-phenylacetyl chloride.    G'=H, N-protecting group, 1-12C alkyl, 3-7C cycloalkyl, aryl-1-6C alkyl, 1-6C alkyl carbonyl, aryl carbonyl, aryl-1-6C-alkyl carbonyl, 1-12C-alkoxy carbonyl, aryloxy carbonyl or aryl-1-6C-alkoxy carbonyl group;    n=1-3;    R'=1-12C alkyl (optionally substituted by -COOH, -CONH2, -OH, -SH, -NH-C(=NH)-NH2, imidazole, indole, -NH2 or 3-7C cycloalkyl, aryl-1-6C-alkyl group).